Pharvaris N.V. (PHVS): Price and Financial Metrics
GET POWR RATINGS... FREE!
PHVS Stock Price Chart Interactive Chart >
PHVS Price/Volume Stats
| Current price | $9.46 | 52-week high | $27.50 |
| Prev. close | $9.42 | 52-week low | $1.77 |
| Day low | $8.88 | Volume | 38,175 |
| Day high | $9.58 | Avg. volume | 101,700 |
| 50-day MA | $7.43 | Dividend yield | N/A |
| 200-day MA | $12.82 | Market Cap | 301.21M |
Pharvaris N.V. (PHVS) Company Bio
Pharvaris B.V. operates as a clinical-stage company. The Company focuses on the discovery and development of novel oral B2-receptor antagonists for the treatment of patients. Pharvaris serves customers in the Netherlands and Switzerland.
Latest PHVS News From Around the Web
Below are the latest news stories about PHARVARIS NV that investors may wish to consider to help them evaluate PHVS as an investment opportunity.
Pharvaris N.V.'s (NASDAQ:PHVS) largest shareholders are private equity firms with 44% ownership, institutions own 26%To get a sense of who is truly in control of Pharvaris N.V. ( NASDAQ:PHVS ), it is important to understand the... |
Pharvaris: Focused Pipeline On Hereditary AngioedemaPharvaris (PHVS) is a company very focused on developing therapies for all sub-types of hereditary angioedema (HAE'). Their pipeline looks like this: Pharvaris pipeline (Pharvaris website) |
Pharvaris (PHVS): Focused Pipeline On Hereditary AngioedemaPharvaris has a pipeline fully focused on HAE and its molecule has a differentiated value proposition. Find out why PHVS stock is a Hold. |
Pharvaris Provides Regulatory, Clinical, and Corporate UpdatesZUG, Switzerland, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today provided business updates and company highlights. Business Updates and Company Highlights Meeting minutes from Type A meeting with U.S. Food and Drug Administration (FDA) received. Pharvaris will conduct a 26-week rodent toxicology study to resolve the clinical holds in the |
Was anything positive for Pharvaris N.V. (PHVS) stock last session?Pharvaris N.V. (NASDAQ:PHVS) marked $9.30 per share on Tuesday, up from a previous closing price of $7.59. While Pharvaris N.V. has overperformed by 22.53%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, PHVS fell by -38.29%, with highs and lows ranging from $27.50 to $1.77, whereas […] |
PHVS Price Returns
| 1-mo | -15.23% |
| 3-mo | 88.22% |
| 6-mo | -56.69% |
| 1-year | -44.35% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -15.91% |
| 2022 | -21.82% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...